CN1556698A - 使用选择性iNOS抑制剂的神经保护治疗方法 - Google Patents

使用选择性iNOS抑制剂的神经保护治疗方法 Download PDF

Info

Publication number
CN1556698A
CN1556698A CNA028185935A CN02818593A CN1556698A CN 1556698 A CN1556698 A CN 1556698A CN A028185935 A CNA028185935 A CN A028185935A CN 02818593 A CN02818593 A CN 02818593A CN 1556698 A CN1556698 A CN 1556698A
Authority
CN
China
Prior art keywords
alkyl
product
alkoxy
halogen
nmr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA028185935A
Other languages
English (en)
Chinese (zh)
Inventor
Pt
P·T·马宁
���ɶ��ؼ�����
J·R·康纳尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia LLC
Original Assignee
Pharmacia LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia LLC filed Critical Pharmacia LLC
Publication of CN1556698A publication Critical patent/CN1556698A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNA028185935A 2001-09-24 2002-09-24 使用选择性iNOS抑制剂的神经保护治疗方法 Pending CN1556698A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/961,521 US20030119826A1 (en) 2001-09-24 2001-09-24 Neuroprotective treatment methods using selective iNOS inhibitors
US09/961,521 2001-09-24

Publications (1)

Publication Number Publication Date
CN1556698A true CN1556698A (zh) 2004-12-22

Family

ID=25504581

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA028185935A Pending CN1556698A (zh) 2001-09-24 2002-09-24 使用选择性iNOS抑制剂的神经保护治疗方法

Country Status (13)

Country Link
US (1) US20030119826A1 (enExample)
EP (1) EP1429752A1 (enExample)
JP (1) JP2005508910A (enExample)
KR (1) KR20040039394A (enExample)
CN (1) CN1556698A (enExample)
AU (1) AU2002327042A2 (enExample)
BR (1) BR0212989A (enExample)
CA (1) CA2455989A1 (enExample)
IL (1) IL161005A0 (enExample)
MX (1) MXPA04002710A (enExample)
PL (1) PL371774A1 (enExample)
WO (1) WO2003026638A1 (enExample)
ZA (1) ZA200402288B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8314124B2 (en) * 2004-02-06 2012-11-20 Active Biotech Ab Crystalline salts of quinoline compounds and methods for preparing them
CN107176923A (zh) * 2005-10-19 2017-09-19 泰华制药工业有限公司 拉奎尼莫钠晶体及其制备方法
KR101495327B1 (ko) 2006-06-12 2015-02-24 테바 파마슈티컬 인더스트리즈 리미티드 안정한 라퀴니모드 제제
US8178127B2 (en) 2007-12-20 2012-05-15 Teva Pharmaceuticals Industries, Ltd. Stable laquinimod preparations
CA2736091A1 (en) * 2008-09-03 2010-03-11 Teva Pharmaceutical Industries Ltd. 2-oxo-1,2-dihydro-quinoline modulators of immune function
CN105616410A (zh) * 2009-07-30 2016-06-01 泰华制药工业有限公司 利用拉喹莫德治疗克隆氏病
ES2731052T3 (es) * 2009-08-10 2019-11-13 Active Biotech Ab Tratamiento de la enfermedad de Huntington usando laquinimod
SG11201401330YA (en) 2011-10-12 2014-05-29 Teva Pharma Treatment of multiple sclerosis with combination of laquinimod and fingolimod
US9161935B2 (en) 2012-02-03 2015-10-20 Teva Pharmaceutical Industries, Ltd. Use of laquinimod for treating Crohn's disease patients who failed first-line anti-TNF therapy
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
CA2890194A1 (en) 2012-11-07 2014-05-15 Teva Pharmaceutical Industries Ltd. Amine salts of laquinimod
WO2014153145A2 (en) 2013-03-14 2014-09-25 Teva Pharmaceutical Industries Ltd. Crystals of laquinimod sodium and improved process for the manufacture thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100835265B1 (ko) * 2000-03-24 2008-06-09 파마시아 코포레이션 산화 질소 신타아제 억제제로 유용한 아미디노 화합물 및그들의 염
AR032318A1 (es) * 2000-04-13 2003-11-05 Pharmacia Corp Compuesto derivado halogenado del acido 2-amino-5,6 heptenoico; composicion farmaceutica que lo comprende y su uso en la fabricacion de un medicamento util como inhibidor de la oxido nitrico sintetasa

Also Published As

Publication number Publication date
CA2455989A1 (en) 2003-04-03
ZA200402288B (en) 2006-12-27
PL371774A1 (en) 2005-06-27
JP2005508910A (ja) 2005-04-07
WO2003026638A1 (en) 2003-04-03
US20030119826A1 (en) 2003-06-26
KR20040039394A (ko) 2004-05-10
IL161005A0 (en) 2004-08-31
MXPA04002710A (es) 2004-07-05
AU2002327042A2 (en) 2003-04-07
BR0212989A (pt) 2005-04-26
EP1429752A1 (en) 2004-06-23

Similar Documents

Publication Publication Date Title
CN1282640C (zh) N－芳基苯乙酰胺衍生物及包含所述化合物的药物组合物
CN1243723C (zh) 作为fsad的nep抑制剂的n－苯丙基环戊基取代的戊二酰胺衍生物
KR101733180B1 (ko) 신규 1-아릴-3-아자바이사이클로［3.1.0］헥산：제조 방법 및 신경 정신 질환 치료를 위한 용도
CN1720029A (zh) 治疗下泌尿道症状的α－2－δ配体
US20200308109A1 (en) Fluorene compound and pharmaceutical use thereof
CN1441785A (zh) 可用作生长激素促分泌素的四氢异喹啉类似物
CN1688577A (zh) 三氮杂螺[5.5]十一烷衍生物及以它为活性成分的药物
CN1444582A (zh) 杂环化合物,它们的制备和用途
CN1310709A (zh) N,n－取代环胺衍生物
CN1556698A (zh) 使用选择性iNOS抑制剂的神经保护治疗方法
CN1993120A (zh) 用于治疗阿尔茨海默氏病的芳基乙酸和相关化合物
CN1626069A (zh) 支链氨基酸依赖性氨基转移酶的抑制剂及其在治疗糖尿病性视网膜病中的应用
CN1863763A (zh) 用于治疗疾病的氨基脲敏感性胺氧化酶(ssao)和vap－1介导的粘着的抑制剂
CN1575282A (zh) 内酰胺化合物
CN101068916A (zh) 阿扎那韦用于改良通过ugt1a1代谢的药物的药物动力学的用途
CN1832937A (zh) 作为乙酰胆碱酯酶抑制剂的他克林衍生物
CN1556707A (zh) 使用选择性iNOS抑制剂的眼科疾病治疗方法
CN1674885A (zh) 治疗和预防胃肠病症的方法
HK1070278A (en) Neuroprotective treatment methods using selective inos inhibitors
CN1304380C (zh) 苯并[a]吩嗪－11－酰胺衍生物及它们作为拓扑异构酶Ⅰ和Ⅱ的联合抑制剂的用途
HK1079429A (en) Methods for treatment and prevention of gastrointestinal conditions
HK1076061A (en) Using a selective inos inhibitor for the treatment of respiratory diseases and conditions
JP2005506986A5 (enExample)
HK1092089A (en) Combinations comprising alpha-2-delta ligands and serotonin/noradrenaline re-uptake inhibitors
HK1060724B (en) N-phenpropylcyclopentyl-substituted glutaramide derivatives as nep inhibitors for fsad

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1070278

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1070278

Country of ref document: HK